Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05303519Phase 3Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Role: collaborator

NCT04617054Phase 2Terminated

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

Role: collaborator

NCT02279433Phase 1Completed

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Role: collaborator

NCT06214793Phase 2Suspended

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Role: collaborator

NCT05609929Phase 1Completed

Study the Effect of Omeprazole on AB-106 Pharmacokinetics

Role: collaborator

NCT05357911Phase 1Completed

A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

Role: collaborator

NCT05814536Phase 1Terminated

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Role: lead

All 7 trials loaded